Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Eli Lilly signs deals to boost supply of COVID-19 treatment in India

05/10/2021 | 04:01am EDT
FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego

BENGALURU (Reuters) -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.

The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.

Baricitinib has been given restricted emergency use approval by India's drug regulator for use in combination with remdesivir for the treatment of hospitalised COVID-19 adult patients requiring supplemental oxygen, Eli Lilly said in an emailed statement.

The U.S. Food and Drug Administration initially gave Lilly an emergency use approval in November for baricitinib in combination with remdesivir to treat COVID-19 patients.

"More licenses to additional Indian generic manufacturers are expected to be announced soon," said Luca Visini, managing director at Lilly India, without elaborating further.

Last week, Lilly said it would donate 400,000 tablets of baricitinib, to be used with remdesivir, to the Indian government.

These agreements would expand the portfolio of COVID-19 drugs offered by the country's drugmakers. All three companies offer antiviral drug favipiravir, used to treat patients with moderate to mild COVID-19.

Cipla, which also offers remdesivir and tocilizumab, said last week it would be the local distribution partner for a COVID-19 antibody drug cocktail developed by Roche and Regeneron, after the therapy got domestic emergency use approval.

Separately, smaller Indian drugmaker Natco Pharma said https://bit.ly/3fa5SU3 earlier this month it would request a compulsory license based on emergency approval for its own generic version of baricitinib.

India reported 366,161 new infections and 3,754 deaths on Monday, dipping from recent peaks, while calls grew for a nationwide lockdown.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.89% 222.67 Delayed Quote.29.44%
NATCO PHARMA LIMITED 0.06% 1096.5 Delayed Quote.13.91%
Latest news "Economy & Forex"
04:36pExxon to cut U.S. workforce by up to 10% annually - Bloomberg News
RE
04:36pEnergy Rebounds As Fed Fears Fade -- Energy Roundup
DJ
04:35pBitcoin falls 8.6% to $32,540
RE
04:34pMortgage-focused Blend Labs aims to raise up to $100 mln in U.S. IPO
RE
04:33pU.S. Supreme Court rebuffs insurers on Obamacare reimbursements
RE
04:32pDelta says it is hiring more than 1,000 pilots by next summer - memo
RE
04:32pDelta says it is hiring more than 1,000 pilots by next summer - memo
RE
04:30pFed's Powell sees 'sustained improvement' in economy, notable rise in inflation
RE
04:21pWALL STREET STOCK EXCHANGE : Wall Street ends sharply higher, led by surging Dow
RE
04:16pMexico sets new deadline for re-do of disputed GM contract vote
RE
Latest news "Economy & Forex"